维莫地吉(Vismodegib) - 药物靶点：SMO_在研适应症：转移性基底细胞癌，基底细胞癌，铂耐药性输卵管癌_专利_临床

This phase Ib trial tests the safety, side effects, and best dose of the combination of vismodegib and atezolizumab in treating patients with non-small cell lung cancer (NSCLC) that has come back after a period of improvement (recurrent) or has spread from where it first started (primary site) to other places in the body (metastatic). Vismodegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving a combination of vismodegib and atezolizumab may be safe, tolerable and/or effective than either drug alone in treating patients with recurrent or metastatic NSCLC.

开始日期2024-12-01

申办/合作机构

Ohio State University Comprehensive Cancer Center

[+1]

NCT06344052 / Recruiting临床2期

A Phase 2 Study to Assess the Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment given as an add-on to hedgehog pathway inhibitor therapy.
Researchers will compare the objective response rate for treated Basal cell carcinoma tumors between 3 treatment Arms.
* Arm 1 participants will receive daily hedgehog pathway inhibitor, and 3 cycles of SP-002 treatment.
* Arm 2 participants will receive daily hedgehog pathway inhibitor, and 1 cycle of SP-002 treatment.
* Arm 3 participants will receive daily hedgehog pathway inhibitor only.

开始日期2024-04-09

申办/合作机构

Stamford Pharmaceuticals, Inc.

NCT05561634 / Not yet recruiting临床2期IIT

Evaluation of Radiotherapy After Complete Response to Sonic Hedgehog Pathway Inhibitors in Patients With Locally Advanced Basal Cell Carcinoma: a Prospective Multicenter Study

Locally advanced basal cell carcinoma (BCC) are large BCCs or BCCs located in areas subject to functional and aesthetic risk following surgery or radiotherapy. In these particular situations, surgery and radiotherapy are sometimes not appropriate, and Sonic Hedgehog inhibitors (SHHi) (Vismodegib and Sonidegib) can be proposed. SHHi are effective treatments in laBCC but most CR patients discontinue treatment because of tolerability. Approximately 65% of the population experience a relapse after discontinuation. A few cases of patients treated concomitantly by radiotherapy and vismodegib have been reported in the literature, suggesting that combining vismodegib and concomitant radiotherapy results in an improved overall response compared to a single modality treatment. There is no study evaluating a "consolidation radiotherapy" after complete response to SHHi. We carry out a prospective multicenter study in order to evaluate consolidation radiotherapy in patients with laBCC after achieving complete response with SHHi, with the hypothesis of reducing recurrence after discontinuation of SHHi.

开始日期2023-07-01

申办/合作机构

Centre Hospitalier Universitaire de Lille

[+1]

100 项与维莫地吉相关的临床结果

登录后查看更多信息

100 项与维莫地吉相关的转化医学

登录后查看更多信息

100 项与维莫地吉相关的专利（医药）

登录后查看更多信息

963

项与维莫地吉相关的文献（医药）

2025-01-01·BIOMATERIALS

Bioactive nanocomposite hydrogel enhances postoperative immunotherapy and bone reconstruction for osteosarcoma treatment

Article

作者: Fu, Hao ; Mi, Bobin ; Yan, Chenchen ; Bian, Liming ; Zeng, Ruiyin ; Chu, Xiangyu ; Wang, Ruinan ; Liu, Guohui ; Liu, Tuozhou ; Lin, Jiali ; Xiong, Yuan ; Hu, Liangcong ; Zhang, Kunyu

Osteosarcoma, a malignant bone tumor often characterized by high hedgehog signaling activity, residual tumor cells, and substantial bone defects, poses significant challenges to both treatment response and postsurgical recovery. Here, we developed a nanocomposite hydrogel for the sustained co-delivery of bioactive magnesium ions, anti-PD-L1 antibody (αPD-L1), and hedgehog pathway antagonist vismodegib, to eradicate residual tumor cells while promoting bone regeneration post-surgery. In a mouse model of tibia osteosarcoma, this hydrogel-mediated combination therapy led to remarkable tumor growth inhibition and hence increased animal survival by enhancing the activity of tumor-suppressed CD8⁺ T cells. Meanwhile, the implanted hydrogel improved the microenvironment of osteogenesis through long-term sustained release of Mg²⁺, facilitating bone defect repair by upregulating the expression of osteogenic genes. After 21 days, the expression levels of ALP, COL1, RUNX2, and BGLAP in the Vis-αPD-L1-Gel group were approximately 4.1, 5.1, 5.5, and 3.4 times higher than those of the control, respectively. We believe that this hydrogel-based combination therapy offers a potentially valuable strategy for treating osteosarcoma and addressing the tumor-related complex bone diseases.

2024-12-01·REPRODUCTIVE TOXICOLOGY

Efcab7 deletion sensitizes mice to the teratogenic effects of gastrulation-stage alcohol exposure

Article

作者: Fish, Eric W. ; Fish, Eric W ; Boschen, Karen E ; Boschen, Karen E. ; Parnell, Scott E ; Parnell, Scott E.

Alcohol exposure during the gastrulation stage of development can disrupt Sonic hedgehog (Shh) signaling and cause eye, craniofacial, and brain defects. One of the genes that regulates Shh signaling is Efcab7, which encodes a protein that facilitates the actions of Smoothened (Smo), a critical component of the Shh pathway. Previous work from our lab has demonstrated that Efcab7 is differentially expressed between two sub-strains of C57BL/6 mice that differ in their sensitivity to gastrulation-stage alcohol exposure. The more alcohol-sensitive C57BL/6 J mice express lower levels of Efcab7 during gastrulation than do the less alcohol-sensitive C57BL/6NHsd mice. The current study examined whether partial or full Efcab7 deletions render mice more sensitive to gastrulation-stage alcohol exposure and affect the sensitivity to other modulators of Shh signaling that cause craniofacial malformations. Efcab7^+/- dams were mated with Efcab7^+/- sires to produce Efcab7^+/+, Efcab7^+/-, and Efcab7^-/- fetuses. On gestational day 7 (GD 7), they received either alcohol (two doses of 2.9 g/kg, i.p., given 4 hours apart), the Smo antagonist vismodegib (40 mg/kg, or vehicle, p.o.), the Smo agonist SAG (20 mg/kg) or the appropriate vehicles. GD 17 fetuses were collected and examined for ocular and craniofacial dysmorphology. As compared to Efcab7^+/+ fetuses, Efcab7^-/- fetuses exposed to alcohol or vismodegib treatment had more severe ocular and craniofacial malformations. In contrast, Efcab7^-/- fetuses had less severe malformations induced by SAG. These results confirm that Efcab7 can modify responses to Shh agonists and antagonists and further identify Efcab7 as a gene important for the sensitivity to gastrulation-stage alcohol exposure.

2024-12-01·CELL BIOCHEMISTRY AND BIOPHYSICS

Combination of Vismodegib and Paclitaxel Enhances Cytotoxicity via Bak-mediated Mitochondrial Damage in EGFR-Mutant Non-Small Cell Lung Cancer Cells

Article

作者: Tu, Yun-Chieh ; Yeh, Wei-Chen ; Yu, Hsin-Hsien ; Lee, Chu-Wan ; Su, Bor-Chyuan ; Hsu, Pei-Ling

Half of NSCLC patients harbor epidermal growth factor receptor (EGFR) mutations, and their therapeutic responses are remarkably different from patients with wild-type EGFR (EGFR-WT) NSCLC. We previously demonstrated that the hedgehog inhibitor vismodegib (Vis) potentiates paclitaxel (PTX)-induced cytotoxicity via suppression of Bax phosphorylation, which promotes accumulation of mitochondrial damage and apoptosis in EGFR-WT NSCLC cells. In this study, we further delineated the anticancer activity and underlying mechanisms of this combination treatment in EGFR-mutant NSCLC cells. MTS/PMS activity and trypan blue exclusion assays were used to assess cell viability. Apoptosis was monitored by chromosome condensation, annexin V staining, and cleavage of PARP and caspase-3. Western blots were conducted to track proteins of interest after treatment. Reactive oxygen species (ROS) level was monitored by 2',7'-dichlorodihydrofluorescein diacetate. Mitochondrial status was analyzed by tetramethylrhodamine, ethyl ester. Hedgehog signaling was induced by PTX, which rendered H1975 and PC9 cells insensitive to PTX-induced mitochondrial apoptosis via suppression of Bak. However, Vis enhanced PTX-induced Bak activation, leading to mitochondrial damage, ROS accumulation, and subsequent apoptosis. Our findings suggest that the combination of Vis and PTX could be a potential therapeutic strategy to increase PTX sensitivity of EGFR-mutant NSCLC.

91

项与维莫地吉相关的新闻（医药）

2024-12-02

·蒲公英Ouryao

最新粤港澳大湾区内地九市临床急需进口港澳药品医疗器械目录

转自：广东省药监局编辑：水晶 12月2日，广东省药监局网省消息，广东省药监局和广东省卫健委发布粤港澳大湾区内地九市临床急需进口港澳药品医疗器械目录（2024年）的通告。《通告》指出，本批目录收录34个上市药品及37个医疗器械。对已列入目录的药械产品，将于2024年12月1日起按照《条例》第九条进行管理。 34个药品：卡那奴单抗、维莫德吉胶囊、盐酸维那卡兰注射液、阿仑珠单抗、罗氟司特片、氨己烯酸薄膜衣片、卡博替尼薄膜衣片、阿培利司薄膜衣片、厄达替尼片、注射用羟钴胺素、布西珠单抗、伊匹木单抗注射液、巴氯芬注射液、艾沙妥昔单抗注射用浓缩液、肾上腺素注射液（预充笔）、莱博雷生片、瑞玛奈珠单抗、硫酸瑞美吉泮口崩片、注射用坦昔妥单抗、二十碳五烯酸乙酯软胶囊、阿扎胞苷片、曲美木单抗、注射用芦比替定、阿司福酶α注射液、阿伏利尤单抗、特泽利尤单抗、磷酸芦可替尼乳膏、罗莫佐单抗、重组人促卵泡素α/促黄体素α注射液、注射用重组人促卵泡素α/促黄体素α、艾普奈珠单抗、伊曲莫德片、依洛硫酸酯酶α注射液、维替索妥尤单抗。根据《广东省粤港澳大湾区内地九市进口港澳药品医疗器械管理条例》（以下简称《条例》）中对急需港澳药械实施目录管理的要求，广东省药品监督管理局、广东省卫生健康委员会经研究决定发布广东省粤港澳大湾区内地九市临床急需港澳药品医疗器械目录（2024年）。本批目录将按《国家药品监督管理局国家卫生健康委员会关于临床急需境外新药审评审批相关事宜的公告》（2018年第79号）发布并符合《条例》要求的港澳已上市药品及《条例》实施前已批准的共71个药品及医疗器械收录。对已列入目录的药械产品，将于2024年12月1日起按照《条例》第九条进行管理。特此通告。附件：1.广东省粤港澳大湾区内地九市临床急需进口港澳药品目录（2024年） 2.广东省粤港澳大湾区内地九市临床急需进口港澳医疗器械目录（2024年）广东省药品监督管理局广东省卫生健康委员会 2024年11月29日

2024-11-28

·今日头条

【Nature子刊】肿瘤边界的免疫学：中山大学张荣欣团队解析结直肠癌治疗的新机制

【导读】错配修复（MMR）缺陷（dMMR）而非MMR缺陷（pMMR）的结直肠癌（CRC）患者，往往能从免疫检查点阻断（ICB）疗法中获益。为了剖析这些不同治疗反应背后的肿瘤微环境（TME），团队整合了空间增强分辨率omics-测序（Stereo-seq）、单细胞RNA测序和多路复用成像分析，绘制了未经治疗和接受过ICB治疗的CRC患者肿瘤的高清空间图。 2024年11月26日，中山大学肿瘤防治中心结直肠科张荣欣教授团队在期刊《Nature Communications》上发表了题为“Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients”的研究论文。研究结果表明，肿瘤-基质边界的空间组织和免疫状态是dMMR和pMMR CRC的一个显著特征，与ICB反应有关。这项研究指出了肿瘤的分子和细胞空间结构在ICB反应中的重要性，提出了重新规划肿瘤-基质边界，以提高大多数CRCs免疫疗法敏感性的可能性。 https://www.nature.com/articles/s41467-024-54710-3 关于结直肠癌 01 免疫检查点阻断（ICB）疗法重新定义了结直肠癌（CRC）患者的治疗。一般来说，DNA错配修复（MMR）缺陷/微卫星不稳定性高（dMMR/MSI-hi）的结直肠癌患者突变负荷较高，往往对ICB疗法敏感，而MMR强化（pMMR）的患者突变负荷通常较低，大多无应答。团队最近报告了在dMMR队列中，抗程序死亡1（PD1）单克隆抗体（mAb，sintilimab）的总体反应率为93.75%（15/16）（12例为完全反应），这有可能使这些患者免于根治性手术。在这项研究中，团队通过分析25例CRC患者的肿瘤标本，其中包括未经治疗的dMMR、pMMR和抗PD1治疗的dMMR患者，应答者（完全应答 (CR)/PR）和非应答者（疾病稳定，SD），生成了CRC空间转录组图谱，并发现了一个300微米（μm）的边界区域，该区域调控免疫细胞流入肿瘤中心区域（>150μm）。在这种肿瘤-基质边界的微观结构中，肿瘤细胞、成纤维细胞、巨噬细胞/树突状细胞（DC）和T细胞亚群之间的相互作用，与dMMR和pMMR CRCs患者不同的免疫状态有关，这可能与他们不同的ICB反应有关。 CXCL14CAFs可能有助于ICB非应答者TME中的有序基质结构和T细胞排异 02 CXCL14CAF可能通过重塑细胞外基质的组织和结构来促进结构屏障的形成，从而导致ICB非应答者的T细胞专属TME。通过使用有转录组学和临床数据的独立ICB治疗的CRC患者队列（GSE205506），团队进一步观察到，与应答者相比，ICB非应答者的CAF中CXCL14表达量和ECM组织特征得分显著更高。在肾细胞癌（RCC，SCP1288）和黑色素瘤（GSE115978）患者的ICB非应答者中，也发现了一致的较高CXCL14表达。这些结果表明， CXCL14在ICB耐药性中发挥了重要作用，支持靶向CXCL14CAFs以破坏肿瘤-基质边界的结构屏障，可能会提高ICB对大多数pMMR CRCs的疗效。 CXCL14CAFs可能是导致ICB无应答者TME中基质结构紊乱和T细胞被排斥的原因。肿瘤细胞可能通过IHH/PTCH1轴促进CXCL14CAFs，从而制约ICB对pMMR CRC患者的疗效 03 与dMMR CRC细胞系（包括HCT116、HCT8和HCT1549）相比，团队观察到pMMR CRC细胞系HT29和SW620中IHH的表达更高。用IHH重组蛋白（Glpbio，5μg/mL）处理CXCL14CAFs，会导致MMP11释放量显著增加。此外，将CXCL14CAFs暴露于pMMR CRC HT29细胞的条件培养基（CM），也会导致类似的MMP11上调。重要的是，这种上调可被IHH inbitior Vismodegib（Selleckchem，25µM）抑制。这些结果表明， pMMR肿瘤细胞与CAF_CXCL14之间可能通过IHH_PTCH1轴相互作用。肿瘤细胞通过IHH/PTCH1轴促进CXCL14CAFs，制约了ICB对pMMR CRC患者的疗效。总结 04 1. 细胞-细胞相互作用：细胞-细胞相互作用在形成协调的多细胞肿瘤-基质边界（0±150µm）中起作用，这可能有助于ICB反应。 2. LAMP3DCs和CXCL13T细胞的作用： LAMP3DCs和CXCL13T细胞的空间分布和调控格局在形成ICB反应者的肿瘤-基质边界方面，具有重要作用。 3. 肿瘤细胞与CXCL14CAF的相互作用：这种相互作用可能导致免疫排斥和对ICB不敏感的TME的形成。 4. TME空间结构的重要性：研究强调了TME空间结构，特别是肿瘤-基质边界对ICB疗效的影响，并指出在pMMR CRCs中通过靶向CXCL14CAFs，来敏化ICB反应的潜力。 5. 免疫细胞的空间分布：免疫细胞的空间分布（而非丰度）可区分对ICB敏感和不敏感的CRC患者的TME。 6. 肿瘤-基质边界的免疫状态：肿瘤-基质边界的独特免疫状态与ICB治疗的临床结果有关。 7. CXCL13对TLS形成的重要性： CXCL13对肿瘤特异性淋巴结构（TLS）的形成至关重要，与多种癌症的ICB治疗效果相关。 8. pMMR CRC对ICB不敏感的机制：由ECM组织失调引起的结构屏障，导致了免疫流入的中断和免疫排斥TME的形成，这可能是pMMR CRC中ICB低反应的原因。 9. 靶向治疗的潜力：研究提供了靶向治疗ICB不敏感的TME形成背后的肿瘤-基质边界的丰富数据集。 10. 未来研究方向：需要在临床前和临床试验中开展更多工作，以评估通过重塑ICB无应答者的TME空间结构，来增敏ICB治疗的潜力。参考资料： 1.Arora, S. et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors. Adv. Ther. 36, 2638–2678 (2019). 2.André, T. et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N. Engl. J. Med. 383, 2207–2218 (2020). 【关于投稿】转化医学网（360zhyx.com）是转化医学核心门户，旨在推动基础研究、临床诊疗和产业的发展，核心内容涵盖组学、检验、免疫、肿瘤、心血管、糖尿病等。如您有最新的研究内容发表，欢迎联系我们进行免费报道（公众号菜单栏-在线客服联系），我们的理念：内容创造价值，转化铸就未来！转化医学网（360zhyx.com）发布的文章旨在介绍前沿医学研究进展，不能作为治疗方案使用；如需获得健康指导，请至正规医院就诊。热门推荐活动点击免费报名 🕓 全国｜2024年12月-2025年03月 ▶ 中国转化医学产业大会 🕓 上海｜2025年02月28日-03月01日 ▶ 第四届长三角单细胞组学技术应用论坛暨空间组学前沿论坛点击对应文字查看详情

免疫疗法临床研究

2024-11-07

·PRNewswire

Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

LEXINGTON, Mass., Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here from the investor section of the Curis website. A replay of the conference call will be available at . About Curis, Inc. Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML and MDS. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at . SOURCE Curis, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

引进/卖出孤儿药财报临床1期

100 项与维莫地吉相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09992	维莫地吉	L01XX43	DB08828

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
转移性基底细胞癌	欧盟	Roche Registration GmbH	2013-07-12
转移性基底细胞癌	冰岛	Roche Registration GmbH	2013-07-12
转移性基底细胞癌	列支敦士登	Roche Registration GmbH	2013-07-12
转移性基底细胞癌	挪威	Roche Registration GmbH	2013-07-12
基底细胞癌	美国	Genentech, Inc.	2012-01-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
铂耐药性输卵管癌	临床2期	美国	Genentech, Inc.	2023-05-15
铂类耐药性原发性腹膜癌	临床2期	美国	Genentech, Inc.	2023-05-15
牙源性肿瘤	临床2期	美国	Genentech, Inc.	2015-10-27
慢性移植物抗宿主病	临床2期	美国	Genentech, Inc.	2015-09-08
类固醇难治性移植物抗宿主病	临床2期	美国	Genentech, Inc.	2015-09-08
特发性肺纤维化	临床2期	-	Hoffmann-La Roche, Inc.	2014-10-01
晚期恶性实体瘤	临床2期	美国	Genentech, Inc.	2014-04-14
胆道癌	临床2期	美国	Genentech, Inc.	2014-04-14
膀胱癌	临床2期	美国	Genentech, Inc.	2014-04-14
唾液腺肿瘤	临床2期	美国	Genentech, Inc.	2014-04-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02091141 (MyPathway, CTgov)	临床2期	晚期恶性实体瘤 \| 膀胱癌 \| 胆道癌 ... 更多	673	Trastuzumab+Pertuzumab (Trastuzumab Plus Pertuzumab)	窪築鏇襯鑰選艱願夢選(鏇艱膚窪範顧醖糧鹽鹹) = 襯鏇窪觸觸艱鏇餘艱糧壓衊淵遞鹽蓋範築願網 (顧鏇獵鬱構糧願鏇窪廠, 鏇糧選廠構遞夢壓鏇繭 ~ 齋蓋鬱選築範築夢糧網) 更多	-	2024-07-23
NCT02091141 (MyPathway, CTgov)	临床2期	晚期恶性实体瘤 \| 膀胱癌 \| 胆道癌 ... 更多	673	atezolizumab (Atezolizumab)	窪築鏇襯鑰選艱願夢選(鏇艱膚窪範顧醖糧鹽鹹) = 積觸遞蓋鹽鬱鑰壓淵繭壓衊淵遞鹽蓋範築願網 (顧鏇獵鬱構糧願鏇窪廠, 蓋積壓廠製選夢艱蓋鬱 ~ 憲淵鏇簾繭遞遞顧簾鬱) 更多	-	2024-07-23
Pubmed 人工标引	临床2期	局部晚期不能切除的乳腺癌诱导	19	Vismodegib	艱衊簾蓋糧廠鏇簾艱鬱(製鹽顧網願積簾憲簾醖) = 簾積憲鬱糧鏇遞鑰艱獵鑰選壓繭襯鑰製範積遞 (構構蓋鬱鑰憲範積窪餘, 68 ~ 98) 更多	积极	2024-04-17
WCD2023	N/A	色素性干皮症	-	Vismodegib 150 mg/day	(觸衊壓觸積膚築窪選簾) = 夢鏇廠夢膚獵艱窪築積憲遞艱願願構遞鬱顧鹽 (築願範網選襯窪齋鬱鑰 )	-	2023-07-03
not applicable (EAN)	N/A	SHH-activated	1	Vismodegib 150 mg	憲網鏇鏇獵簾觸鏇艱餘(蓋鏇蓋獵鑰鬱鑰製鏇蓋) = The treatment was well tolerated, except for increased creatine phosphokinase (CTCAE v3.0 grade 1) 簾艱鏇積願夢襯蓋糧積 (憲醖遞遞鬱壓繭製壓鏇 ) 更多	积极	2023-06-28
NCT02436408 (VISORB \| VISORB trial, CTgov)	临床4期	基底细胞癌	35	Vismodegib	餘襯鹽願構廠構獵網餘(淵糧襯鬱簾遞淵鬱鬱夢) = 遞範夢淵積齋醖構襯鏇衊鏇餘鏇夢衊簾願鑰壓 (艱餘餘繭顧選願廠獵顧, 窪積範糧構網窪衊顧築 ~ 選廠膚鑰鬱鏇遞積鑰願) 更多	-	2021-10-28
ASN2021	N/A	-	-	Vismodegib	窪夢觸築齋窪鑰簾醖醖(餘鑰艱壓廠壓製願壓醖) = 蓋窪鏇鏇餘選製網艱鑰製繭遞鹽夢製鬱網醖齋 (壓艱範鹽觸觸範糧繭壓 )	积极	2021-10-27
NCT02337517 (CTgov)	临床2期	类固醇难治性移植物抗宿主病 \| 慢性移植物抗宿主病	6	Laboratory Biomarker Analysis+Vismodegib	遞壓艱衊鬱鬱淵選鬱夢(獵糧膚襯夢範齋網構繭) = 網襯衊壓鑰築簾繭鏇壓餘鹹製襯醖遞醖積範範 (簾遞壓鏇範鏇齋窪繭網, 製糧繭獵廠蓋憲鑰鏇製 ~ 願積壓積鏇膚齋鹹齋製) 更多	-	2021-06-16
NCT02667574 (VISMONEO, Pubmed) 人工标引	临床2期	基底细胞癌新辅助	55	Vismodegib	襯願鑰鑰鑰衊網衊願網(繭構鑰鹹鑰簾鏇蓋構鏇) = 遞鏇鬱壓廠獵窪膚鬱獵壓鑰夢鑰簾觸築鑰網餘 (選鬱簾製獵鏇鏇範醖繭, 67 ~ 90) 更多	积极	2021-04-26
NCT00957229 (GDC-0449, CTgov)	临床2期	基底细胞痣综合征	41	GDC-0449 (Sugar Pill)	構網繭廠鬱構齋繭選壓(鑰積廠壓繭齋窪糧網顧) = 繭觸簾窪鬱餘鏇夢艱鹽窪顧壓壓醖艱鬱獵廠憲 (積襯醖齋選蓋餘鏇齋憲, 繭繭遞艱鹹鏇願醖夢窪 ~ 簾鏇廠襯構顧壓鑰遞鏇) 更多	-	2021-01-11
NCT00957229 (GDC-0449, CTgov)	临床2期	基底细胞痣综合征	41	GDC-0449 (GDC-0449)	構網繭廠鬱構齋繭選壓(鑰積廠壓繭齋窪糧網顧) = 獵鹽夢鬱願願構廠築製窪顧壓壓醖艱鬱獵廠憲 (積襯醖齋選蓋餘鏇齋憲, 願憲餘衊鹽醖繭憲鹽齋 ~ 醖繭鏇鹹簾簾構繭淵餘) 更多	-	2021-01-11
ESMO_ASIA_VIRTUAL2020	N/A	转移性基底细胞癌	29	Vismodegib	糧鹹網糧餘齋蓋蓋獵鏇(餘簾蓋獵顧鑰廠構鹽壓) = 13.8% 齋鹹壓窪憲觸廠餘構築 (簾積鏇窪獵壓壓餘鑰構 ) 更多	积极	2020-11-22